

## Brief Biography

<b>Name</b>	Jae-ho, Yoon, MD	
<b>Major</b>	Department of Hematology	
<b>Education</b>	1997.3 – 2003.2 Bachelor's degree The Catholic university of Korea, Seoul, Korea 2010.3 – 2014.2 Degree of master of internal medicine The Catholic Univ. of Korea, graduate school, in school	
<b>Position</b>	2003.03 – 2008.02 Internship plus resident, Department of Internal Medicine, Catholic medical center, The Catholic Univ. of Korea 2011.05 – 2018.02 Clinical Fellowship and assistant professor, 2018.03 – 2020.02 Assistant professor, Department of Hematology, Catholic Hematology Hospital, Korea 2021.02 – 2022.01. US Memorial Sloan Kettering Cancer Center, Visiting investigator 2022.02 – 2022.07 Canada University of Ottawa Department of BMI, Visiting investigator 2020.03 - Present Associate professor, Department of Hematology, Catholic Hematology Hospital, Korea	
<b>Awards</b>	2012 Best abstract of KJH. The 53 <sup>rd</sup> Congress of the Korean Society of Hematology 2013 Award for the best abstract, The 18 <sup>th</sup> Congress of the Korean Society of BMT 2015 Award for the best research paper, The Korean Journal of Internal Medicine. 2017 Award for the best young investigator, Korean Society of Hematology 2018 Award for the best young investigator, Korean Society of BMT 2020 Award for the best young investigator, Korean Society of Hematology 2022 Award for the best abstract, Korean Society of Hematology 2023 Award for the leading investigator, Korean Society of BMT 2023 Award for the best oral presentation, Asian-Pacific Bone Marrow Transplantation	
<b>Activity</b>	Korean Society of Hematology Korean Society of Hematopoietic Stem Cell Transplantation Korean Society of Internal Medicine American Society of Hematology	
<b>Research papers</b>	Sung KH, <b>Yoon JH (Correspondence)</b> , Kwag D, Min GJ, Park SS, Park S, Lee SE, et al. Atypical features of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after inotuzumab ozogamicin in adult patients with acute lymphoblastic leukemia. Blood research. 2025;60(1):28. Park SY, <b>Yoon JH (Correspondence)</b> , Kwag D, Jung J, Min GJ, Park SS, Park S, et al. Poor prognostic implication of CDKN2 deletion in adult patients with Philadelphia chromosome-positive ALL. Blood cancer journal. 2025;15(1):102. Lee S, <b>Yoon JH (Correspondence)</b> , Kwag D, Min GJ, Park SS, Park S, et al. Comparison of Long-Term Outcomes of Double Unit Cord Blood Versus Haploidentical Donor Transplantation in Adult Patients With Acute Lymphoblastic Leukemia Regarding KIR-Ligand Mismatch. Clin Lymphoma Myeloma Leuk. 2025;25(1):e11-e25 e1. Kwag D, <b>Yoon JH (Correspondence)</b> , Min GJ, Park SS, Park S, Lee SE, et al. Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents. Bone Marrow Transplant. 2025;60(9):1249-57. Baek HS, <b>Yoon JH (Correspondence)</b> , Lee JH, Lee J, Lee SH, Min GJ, Park SS, et al. Association between body mass index and survival after hematopoietic stem cell transplantation. The Korean journal of internal medicine. 2025;40(4):645-56. Ahn J, <b>Yoon JH (Correspondence)</b> , Kwag D, Min GJ, Park SS, Park S, Lee SE, et al. Feasibility of a Total Body Irradiation-Augmented Reduced-Toxicity Conditioning Regimen with an Antithymocyte Globulin/Post-Transplantation Cyclophosphamide Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2025;31(8):588 e1- e11.	

Ahn J, **Yoon JH (Co-first author)**, Kwag D, Min GJ, Park SS, Park S, et al. Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia. *Bone Marrow Transplant*. 2024.

**Yoon JH**, Lee S. Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy. *The Korean journal of internal medicine*. 2024;39(1):34-56.

**Yoon JH**, Kwag D, Lee JH, Min GJ, Park SS, Park S, et al. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis. *Therapeutic advances in hematology*. 2023;14:20406207231154713.

**Yoon JH**, Kim HS, Min GJ, Park SS, Park S, Lee SE, et al. Cytogenetic and molecular characteristics and outcomes of adult patients with early T-cell precursor acute lymphoblastic leukemia. *Eur J Haematol*. 2023;110(2):137-48.

**Yoon JH**, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality. *Therapeutic advances in hematology*. 2022

Lee SH, **Yoon JH (Co-first author)**, Min GJ, Park SS, Park S, Lee SE, et al. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. *Int J Hematol*. 2022;115(1):135-9.

Lee S, **Yoon JH (Correspondence)**, Lee E, Park SS, Park MS, Jung J, Min GJ, et al. Prediction and recommendation by machine learning through repetitive internal validation for hepatic veno-occlusive disease/sinusoidal obstruction syndrome and early death after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2022.

Kwag D, **Yoon JH (Correspondence)**, Min GJ, Park SS, Park S, Lee SE, et al. Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response. *Acta Haematol*. 2022.

Lee J, **Yoon JH (Co-first author)**, Kwag D, Lee JH, Kim TY, Min GJ, et al. Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy. *Therapeutic advances in hematology*. 2021;12:20406207211066176.

Cho H, Kim Y, **Yoon JH (Co-first author)**, Lee J, Lee GD, Son J, et al. Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia. *Bone Marrow Transplant*. 2021.

**Yoon JH**, Choi CW, Won JH. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea. *The Korean journal of internal medicine*. 2021.

Oh EJ, **Yoon JH (Correspondence)**, Park KH, Bae HJ, Yun SJ, Min GJ, et al. Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study. *Therapeutic advances in hematology*. 2021;12:20406207211020544.

**Yoon JH**, Min GJ, Park SS, Park S, Lee SE, Cho BS et al. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. *Bone Marrow Transplant* 2021. e-pub ahead of print 2021/02/03; doi: 10.1038/s41409-021-01215-y

**Yoon JH**, Min GJ, Park SS, Park S, Lee SE, Cho BS et al. Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. *Bone Marrow Transplant* 2021; 56(4): 828-840. e-pub ahead of print 2020/11/01; doi: 10.1038/s41409-020-01097-6

**Yoon JH**, Park SS, Min GJ, Park S, Lee SE, Cho BS et al. Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis. *Therapeutic advances in hematology* 2020; 11: 2040620720932038. e-pub ahead of print 2020/07/14

**Yoon JH**, Min GJ, Park SS, Park S, Lee SE, Cho BS et al. HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis. *Therapeutic advances in hematology* 2020; 11: 2040620720936935. e-pub ahead of print 2020/10/01

Yoon SY, **Yoon JH (Co-first author)**, Min GJ, Park SS, Park S, Lee SE et al. Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant* 2020; 55(7): 1469-1472

**Yoon JH**, Min GJ, Park SS, Park S, Lee SE, Cho BS et al. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. *Cancer medicine* 2019. doi: 10.1002/cam4.2680

**Yoon JH**, Kim HJ, Min GJ, Park SS, Jeon YW, Lee SE, et al. Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia. *Scientific reports*. 2019;9(1):11935.

**Yoon JH**, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. *Cancer*. 2019;125(6):873-83.

**Yoon JH**, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiopeta for high-risk or relapsed lymphomas. *Bone Marrow Transplant*. 2019;54(2):330-3.

**Yoon JH**, Park SS, Jeon YW, Lee SE, Cho BS, Eom KS, et al. Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. *Haematologica*. 2019;104(2):269-76.

**Yoon JH**, Yoo KH, Sung KW, Jung CW, Kim JS, Hahn SM, et al. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). *Bone Marrow Transplant*. 2019;54(8):1361-8.

<https://www.linkedin.com/in/jae-ho-yoon-82394925a/>

